Phase II Study of TKI258 (Dovitinib) Monotherapy in Patients With Unresectable Adenoid Cystic Carcinoma.

Next Previous
Trial Profile

Phase II Study of TKI258 (Dovitinib) Monotherapy in Patients With Unresectable Adenoid Cystic Carcinoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Apr 2015

At a glance

  • Drugs Dovitinib (Primary)
  • Indications Adenocarcinoma
  • Focus Therapeutic Use

    • Most Recent Events

    • 11 Nov 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 11 Apr 2013 Planned end date changed from 1 Sep 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.
    • 31 Oct 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top